MondayNightIBD ~ Treat-to-Target Clinical Convo
October 21, 2024 ~ Jami Kinnucan, MD
Post-Survey & Application for CME Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. What are your specialty & credentials?

IBD Specialist

General GI

Colorectal Surgeon

Fellow/Trainee

APP

Nurse

PharmD

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

* 3. In the CALM study comparing conventional treatment vs T2T treatment escalation in bionaive Crohn's patients starting adalimumab, mucosal healing at week 48 was defined as?

(CDEIS: Crohn's Disease Endoscopic Index of Severity)

CDEIS 0 and no ulcers

CDEIS = 0 (normal exam)

CDEIS <4 and no deep ulcers

Deep ulcers< 10% of bowel surface

Question Title

* 4. 55 with recent diagnosis of colonic Crohn’s disease, SESCD 6, FCP 850, started on Vedolizumab. At 3 month FCP 100, Colonoscopy at 1yr : endo remission.

According to the AGA 2023 guidelines, how can you periodically (every few months) rule out active inflammation moving forward?

Clincial symtoms check

FCP check <150

Endoscopy

CT or MRI

EVALUATION FORM

Question Title

* 5. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease	Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease Strongly agree	Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease Agree	Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease Disagree	Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease Strongly disagree

Question Title

* 6. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree

Question Title

* 7. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

* 8. If no, please explain:

Question Title

* 9. Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Identify patients at a high-risk of progressive disease

Appropriately assess disease activity

Apply STRIDE-II recommendations to treatments plans

Initiate advanced therapies earlier for patients at high-risk of progression

Utilize tight control treatment strategies

Individualize treatment targets using objective targets of disease control and work with patients to identify which targets are important to them

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

* 11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding treatment options (patient-related)

Patient adherence/resistance to new therapeutics and/or clinical trial enrollment (patient-related barrier)

Limited knowledge regarding new therapeutics for <insert disease state here> (provider-level barrier)

Lack of time resources to consider change (practice-related barrier)

Inadequate support staff for pt education/insurance/billing/administrative issues (practice-level barrier)

Insurance reimbursement or legal issues (systems-related barrier)

Lack of access to novel therapeutics due to regulatory approvals/insurance coverage (systems-related barrier)

Other (please specify)

Question Title

* 12. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information.

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Treat-to-Target" and claim 1.0 AMA PRA Category 1 Credit^TM.

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

MondayNightIBD ~ Treat-to-Target Clinical ConvoOctober 21, 2024 ~ Jami Kinnucan, MD***Post-Survey & Application for CME Credit***

Question Title

* 1. What are your specialty & credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. In the CALM study comparing conventional treatment vs T2T treatment escalation in bionaive Crohn's patients starting adalimumab, mucosal healing at week 48 was defined as? (CDEIS: Crohn's Disease Endoscopic Index of Severity)

Question Title

* 4. 55 with recent diagnosis of colonic Crohn’s disease, SESCD 6, FCP 850, started on Vedolizumab. At 3 month FCP 100, Colonoscopy at 1yr : endo remission. According to the AGA 2023 guidelines, how can you periodically (every few months) rule out active inflammation moving forward?

Question Title

* 5. Upon completion of this activity, I am able to:

Question Title

* 6. Please indicate the extent of your agreement with the following statements:

Question Title

* 7. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 8. If no, please explain:

Question Title

* 9. Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 12. For purposes of certification, you must complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Treat-to-Target" and claim 1.0 AMA PRA Category 1 CreditTM.

MondayNightIBD ~ Treat-to-Target Clinical Convo
October 21, 2024 ~ Jami Kinnucan, MD
Post-Survey & Application for CME Credit

* 3. In the CALM study comparing conventional treatment vs T2T treatment escalation in bionaive Crohn's patients starting adalimumab, mucosal healing at week 48 was defined as?

(CDEIS: Crohn's Disease Endoscopic Index of Severity)

* 4. 55 with recent diagnosis of colonic Crohn’s disease, SESCD 6, FCP 850, started on Vedolizumab. At 3 month FCP 100, Colonoscopy at 1yr : endo remission.

According to the AGA 2023 guidelines, how can you periodically (every few months) rule out active inflammation moving forward?

* 12. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information.

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Treat-to-Target" and claim 1.0 AMA PRA Category 1 Credit^TM.